Trial Profile
Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patients With Relapsed and Refractory PTCL
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Durvalumab (Primary) ; Pralatrexate (Primary) ; Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- 16 Mar 2022 Planned End Date changed from 1 Feb 2021 to 1 Feb 2023.
- 16 Mar 2022 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2023.
- 08 Oct 2020 According to a Food and Drug Administration media release, the FDA has awarded research grant of $3.2 million over four years to the principal investigator Owen O'Connor, University of Virginia (Charlottesville, Virginia) to conduct this trial.